Skip to main content

01.11.2005 | Clinical Investigation | Ausgabe 11/2005

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2005

Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years’ experience

Graefe's Archive for Clinical and Experimental Ophthalmology > Ausgabe 11/2005
Madhavi Kurli, Paul T. Finger
Wichtige Hinweise
Presented (in part) at the American Academy of Ophthalmology Annual Meeting, New Orleans, October 2004.



To report 12-year follow-up experience with topical mitomycin chemotherapy for diffuse and multifocal primary acquired melanosis (PAM) with atypia and conjunctival melanoma.


Interventional case series of 16 patients. Mitomycin was a primary treatment for residual epithelial disease in ten patients (eight with PAM with atypia and two with conjunctival melanoma) and as an adjuvant to excision and cryotherapy in six with conjunctival malignant melanoma. Primary treatments consisted of mitomycin 0.04% qid for 28 days (two 14-day cycles) and for 7 consecutive days as adjuvant therapy. Patients were followed for both local recurrence and metastatic disease.


Sixteen patients were followed for a mean 81 months (range 13–144 months) after treatment. All tumors responded to chemotherapy. Recurrence was noted in eight (three adjuvant and five primary treatment patients). Three underwent orbital exenteration. The remaining five were treated conservatively. The mean time to recurrence was 36.9 months. The short-term mitomycin-related complications included transient keratoconjunctivitis (n=14), severe keratoconjunctivitis (n=1) and one corneal abrasion with scar formation. The long-term complications included pannus (n=2) and corneal haze (n=1). Visual acuity was maintained within two lines in 14 patients (including measurements just prior to exenteration). Three patients died, one of metastatic conjunctival melanoma.


Conjunctival melanoma and PAM responded to mitomycin 0.04% topical chemotherapy; subepithelial nests appeared resistant to treatment. Treatment-related complications were acceptable. In this series, as primary and adjuvant therapy, topical mitomycin yielded an overall recurrence rate of 50%.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

Über diesen Artikel

Weitere Artikel der Ausgabe 11/2005

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2005 Zur Ausgabe



Neu im Fachgebiet Augenheilkunde

21.04.2021 | Glaukom | CME | Ausgabe 6/2021

Optische Kohärenztomographie-Angiographie (OCT-A)

Überblick über die Technik und Anwendungsmöglichkeiten in Klinik und Wissenschaft

09.04.2021 | DFP-Fortbildung | Ausgabe 2/2021

Anteriore virale Uveitis

Klinik, diagnostisches Vorgehen und Behandlungsoptionen